About Chronic Kidney Disease
Chronic Kidney Disease (CKD) is a worldwide public health problem with steadily increasing incidence, prevalence, and cost. Key factors driving CKD in developed countries include aging populations and the current epidemic of obesity and its associated complications of hypertension and adult-onset diabetes.
In North America, there are currently over 47million patients with CKD. According to the National Kidney Foundation (NFK), about 21 million North American patients suffer from moderate CKD (stages 3 and 4) to severe CKD (stage 5). Stages 3 and 4 are characterized by progressively decreasing kidney function as measured by glomerular filtration rate. In Stage 5, kidney function is minimal to altogether absent, and patients require regular dialysis or kidney transplant for survival. An estimated 71-97% of CKD patients have vitamin D insufficiency, which can lead to secondary hyperparathyroidism (SHPT) and resultant debilitating diseases including bone disease, markedly increased bone fracture rates, pervasive soft tissue calcification, cardiovascular disease, muscle weakness and reduced quality of life.